Acute Intermittent Porphyria Market Growth and Value Chain Analysis 2018 – 2026

Acute intermittent porphyria (AIP) is a hereditary metabolic disorder. It affects the production of heme, which is the prosthetic group of hemoglobin binding to oxygen. It is caused due to low enzyme porphobilinogen deaminase. The main reasons for acute intermittent porphyria are insomnia, anorexia, and change in coloration of urine, myalgia, and retention of urine. At times, AIP results in the formation of liver tumor (hepatocellular carcinoma) and kidney failure.

Request Brochure-

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42014

Some of the symptoms also mention issues related to gastrointestinal tract, urinary tract, psychological and neurological issues. The disease is considered to be rare. Porphyria is caused by the development of chemicals in the body that create a substance called porphyrin. Acute intermittent porphyria is a hereditary metabolic disorder and is one of the eight kinds of porphyria. If any of the parent is suffering from this disorder, the child has 50% chance of inheriting any of the eight porphyria disorders.

The market in Europe is driven by increased research and development supported by funds from governments and increase in geriatric population. However, the acute intermittent porphyria market in Asia Pacific is expected to grow at a rapid pace during the forecast period owing to rise in awareness about health care technologies, large patient population, and presence of continuously developing economies providing significant opportunities in this acute intermittent porphyria market. Additionally, Middle East & Africa has witnessed an increase in blood disorders due to ignorance of diseased conditions and poor economy leading to limited access to treatment.

The global acute intermittent porphyria market is dominated by key players such as Siemens AG, Boston Scientific Corporation, Danaher, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., ARKRAY, Inc., ACON Laboratories, Inc., Sonova Holding AG, C. R. Bard, Inc., Sysmex Corporation, and Nurotron Biotechnology Co. Ltd.

Request For Discount-

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=42014

The report offers a comprehensive evaluation of the acute intermittent porphyria market. It does so via in-depth qualitative insights, historical data, and verifiable projections about acute intermittent porphyria market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website:www.transparencymarketresearch.com

This release was published on openPR.